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Objectives We sought to evaluate whether pre-procedural glucose levels are associated with contrast-induced acute kidney
injury (CI-AKI) after coronary angiography.
Background Although diabetes is a known risk factor for CI-AKI in patients undergoing coronary angiography, whether elevated pre-
procedural glucose levels (regardless of pre-existing diabetes) are associated with higher risk for CI-AKI is unknown.
Methods We evaluated 6,358 patients with acute myocardial infarctions undergoing coronary angiography. Patients were stratified
into 5 pre-procedural glucose groups:110mg/dl, 110 to140mg/dl, 140 to170mg/dl, 170 to200mg/dl, and
200mg/dl. Logistic regression models were used to evaluate the relationship between glucose levels and risk for CI-AKI,
first in the entire cohort and then in patients with and without established diabetes. The primary outcome was CI-AKI (0.3
mg/dl absolute or50% relative serum creatinine increase during 48 h after the procedure).
Results The relationship between pre-procedural glucose and CI-AKI varied markedly in patients with and without diabe-
tes. There was a strong association between glucose and CI-AKI risk in patients without diabetes (CI-AKI rates
across the 5 glucose groups from lowest to highest: 8.2%, 9.9%, 12.4%, 14.9%, and 24.3%; p  0.001), but not
in patients with diabetes (20.9%, 16.1%, 16.3%, 14.8%, and 19.2%, respectively; p  0.24; p for glucose  dia-
betes interaction 0.001). After adjusting for confounders (including baseline glomerular filtration rate), the re-
lationship between higher glucose and greater CI-AKI risk persisted in patients without diabetes (odds ratios
[95% confidence intervals] for glucose groups of 110 to 140 mg/dl, 140 to 170, mg/dl 170 to 200 mg/dl,
and 200 mg/dl: 1.31 [1.00 to 1.71], 1.51 [1.11 to 2.10], 1.58 [1.03 to 2.43], and 2.14 [1.46 to 3.14] vs. glu-
cose 110 mg/dl, respectively), but this relationship was not seen in patients with established diabetes.
Conclusions Elevated pre-procedural glucose is associated with greater risk for CI-AKI in patients without known diabetes
who undergo coronary angiography in the setting of acute myocardial infarction. Measures used to prevent CI-
AKI should be considered in these patients. (J Am Coll Cardiol 2010;55:1433–40) © 2010 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.09.072m
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lication of coronary angiography that occurs commonly in
he setting of acute myocardial infarction (AMI) (1,2) and is
ssociated with severe adverse events, including permanent
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Glucose and Contrast-Induced Acute Kidney Injury April 6, 2010:1433–40posed pathophysiologic mecha-
nisms through which contrast ad-
ministration may potentiate renal
injury include oxidative stress, free
radical damage, and endothelial
dysfunction (3,14,15). All of these
processes also are activated in the
setting of hyperglycemia (3,16),
which is common in patients with
AMIs (17) and has adverse prog-
nostic implications (16,18–20),
particularly among those who do
not have established diabetes
(19–21). Thus, it is possible that a
ombination of pre-procedural hyperglycemia and contrast
xposure during coronary angiography could significantly in-
rease the risk for CI-AKI.
However, while diabetes is a well-recognized risk factor
or CI-AKI (10,12,14), the association between pre-
rocedural blood glucose levels and CI-AKI risk (regardless
f pre-existing diabetes) is unknown. Since nearly 50% of
yperglycemic AMI patients do not have known diabetes
22), establishing whether elevated glucose levels before
oronary angiography are related to subsequent CI-AKI risk
ould have important clinical implications; primarily by
dentifying a previously unrecognized high-risk group that
ight benefit from pre-procedural CI-AKI prophylaxis and
lso by highlighting a potential target for intervention in the
revention of CI-AKI.
Accordingly, we analyzed data from the Cerner Corpo-
ation’s (Kansas City, Missouri) Health Facts database, a
ontemporary registry of patients admitted to 40 hospitals
cross the U.S., to define the association between pre-
rocedural hyperglycemia and the risk for CI-AKI during
MI. This database was selected because of its extensive
ollection of laboratory data, including detailed glucose
easurements and assessments of renal function, in a large
onsecutive cohort of AMI patients. We specifically sought
o determine the relationship between pre-procedural glu-
ose levels and the risk for subsequent CI-AKI among
atients with and without known diabetes who are referred
or coronary angiography in the setting of AMI.
ethods
ata source. Details of the Health Facts database have
een described previously (22). Between January 1, 2000,
nd December 31, 2005, the Health Facts database col-
ected deidentified information regarding consecutive pa-
ients hospitalized at 40 U.S. medical centers. Variables
ncluded demographics, medical history, and comorbidities
determined from International Classification of Diseases-
inth Revision billing codes), laboratory studies (including
ll venous and fingerstick blood glucose measurements, as
ell as all serum creatinine levels during hospitalization),
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
CABG  coronary artery
bypass grafting
CI-AKI  contrast-induced
acute kidney injury
GFR  glomerular filtration
rate
PCI  percutaneous
coronary interventionedications, in-hospital procedures (including coronary 1ngiography and percutaneous coronary intervention
PCI]), in-hospital mortality, and hospital characteristics
geographic region, number of beds, surgical and procedural
apabilities, and teaching vs. nonteaching status).
atient population. We identified all patients hospitalized
ith primary discharge diagnoses of AMI (using Interna-
ional Classification of Diseases-Ninth Revision-Clinical
odification codes 410.xx and excluding 410.x2, which
epresents readmission after AMI) who had glucose mea-
urements on admission and at least 1 documented abnor-
al troponin or creatine kinase-myocardial band level.
ubsequently, those patients who were transferred from or
o other acute care facilities were excluded, as complete
aboratory and medication administration details for the
ntire episode of AMI care were not available. For this
nalysis, we further restricted the sample to those who
nderwent coronary angiography during the AMI hospital-
zation and whose laboratory studies included at least 1
re-procedural measurement of serum creatinine and at
east 1 repeat evaluation within 48 h after the procedure. Of
,786 AMI patients who underwent coronary angiography
uring the index hospitalization, 6,358 patients (72%) had
omplete pre- and post-procedural laboratory data and
omprised the study cohort.
lucose assessment and diabetes definition. The Health
acts database provided access to all of the patients’ glucose
alues, including their measurement times. For clarity, all
lasma and capillary glucose measurements are subsequently
eferred to as “blood glucose.” The glucose level evaluated
or each patient was the pre-procedural measurement ob-
ained closest to the time of diagnostic angiography. As in
rior studies (22–24), patients were classified as having
ecognized diabetes if they had corresponding International
lassification of Diseases-Ninth Revision-Clinical Modi-
cation codes or were treated with an oral antihypergly-
emic agent or any extended-release insulin during the
ospitalization.
utcomes. The outcome for this study was the occurrence
f CI-AKI, defined as an absolute serum creatinine increase
0.3 mg/dl or a relative increase in serum creatinine 50%
hat occurred within 48 h after coronary angiography, in
ccordance with the Acute Kidney Injury Network criteria
25). The rates of CI-AKI were calculated using pre- and
ost-procedural serum creatinine measurements. Pre-
rocedural serum creatinine level was defined as the mea-
urement obtained during hospitalization that occurred
efore and closest to the time of coronary angiography.
ost-procedural creatinine level was defined as the highest
erum creatinine measurement within 48 h after coronary
ngiography. If a patient underwent more than 1 coronary
ngiography procedure, pre- and post-procedural creatinine
evels for the first procedure were considered for this
nalysis.
tatistical analysis. Patients were stratified into 5 groups
ccording to pre-procedural glucose levels: 110 mg/dl,
10 to 140 mg/dl, 140 to 170 mg/dl, 170 to 200
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April 6, 2010:1433–40 Glucose and Contrast-Induced Acute Kidney Injuryg/dl, and 200 mg/dl. Baseline characteristics were com-
ared among groups using chi-square analysis for categori-
al variables and analysis of variance for continuous
ariables.
Rates of CI-AKI were compared between subgroups of
re-procedural glucose levels using chi-square analysis, first
n the entire sample and then within the a priori defined
ubgroups of patients with and without known diabetes.
ultivariable logistic regression models were subsequently
eveloped to evaluate whether the association between
re-procedural glucose values and CI-AKI persisted after
djustment for other patient characteristics and potential
onfounders. In these models, pre-procedural glucose level
as included as a categorical variable, using the 5 groups
escribed previously. Patient characteristics clinically con-
idered to be prognostically important, and covariates iden-
ified in bivariate analyses as predictors of CI-AKI (at a level
f significance of p  0.05), were entered into the models.
ovariates included demographic factors (age, gender, and
ace), comorbidities (diabetes, heart failure, hypertension,
nd cerebrovascular disease), laboratory values (admission
ematocrit and peak troponin value), mechanical reperfu-
ion during hospitalization (coronary artery bypass grafting
CABG] or PCI), medications during hospitalization (as-
irin, clopidogrel, ticlopidine, beta-blockers, calcium-
hannel blockers, angiotensin-converting enzyme inhibitors
r angiotensin receptor blockers, diuretics, 3-hydroxy-3-
ethylglutaryl coenzyme A reductase inhibitors, oral anti-
yperglycemic agents, and insulin), hospital site, and hos-
ital length of stay. A pre-procedural glucose  diabetes
nteraction term was also introduced into the models to
ormally test whether the glucose-associated risk for CI-
KI differed in patients with and without known diabetes.
Importantly, the models also adjusted for the baseline
stimated glomerular filtration rate (GFR), calculated ac-
ording to the Modification of Diet in Renal Disease study
quation (26). Because contrast volume is a significant factor
n the development of CI-AKI (1), models adjusted for the
erformance of PCI (categorized as none, single vessel, or
ultivessel), as well as the number of coronary angiography
nd PCI procedures during hospitalization (all surrogates of
ontrast volume). In addition, to account for pre-procedural
I-AKI prophylaxis measures, the final models also ad-
usted for the administration of sodium bicarbonate. Models
ere then repeated within the subgroups of patients with
nd without diabetes.
Several sensitivity analyses were performed. First, multi-
ariable models were repeated after excluding all patients
ho underwent CABG within 48 h of coronary angiogra-
hy, to ensure that our results were not confounded by the
otential impact of CABG on renal function. Second,
ardiogenic shock was incorporated as a covariate into the
odels, given its associations with both hyperglycemia and
I-AKI (2,19). Third, a different definition of CI-AKI was
sed (increase in serum creatinine 0.5 mg/dl or 25%). lecondary analyses. Additional analyses were performed
o examine whether the relationship between pre-procedural
lucose levels and CI-AKI differed according to baseline
enal function. To accomplish this, patients were divided
nto 3 groups according to baseline GFR (30 ml/min, 30
o 59 ml/min, and60 ml/min). The rates of CI-AKI were
hen compared across the 5 pre-procedural glucose catego-
ies (110 mg/dl, 110 to 140 mg/dl, 140 to 170 mg/dl,
70 to 200 mg/dl, and 200 mg/dl) within each of the
FR subclasses, using chi-square analysis. These analyses
ere then performed separately in patients with and without
iabetes.
A 2-sided p value of 0.05 was considered statistically
ignificant. Analyses were conducted with SAS version 8.02
SAS Institute Inc., Cary, North Carolina). Use of the
ealth Facts database was approved by the Saint Luke’s
id America Heart Institute Institutional Review Board.
esults
aseline characteristics. Baseline characteristics are de-
ailed in Table 1, stratified by pre-procedural glucose levels.
re-procedural hyperglycemia (glucose 140 mg/dl) oc-
urred in 42% of the patient sample, and 48% of patients
ith elevated glucose before coronary angiography did not
ave known diabetes. The median time from pre-procedural
lucose assessment to coronary angiography was 8.3 h
interquartile range: 5.3 to 16.3 h). Diabetes was present in
,929 patients (30%). Overall, 823 patients (13%) developed
I-AKI after coronary angiography. Mean creatinine in
hese patients increased from 1.73  1.5 mg/dl at baseline
o a peak of 2.54  1.8 mg/dl, whereas patients without
I-AKI experienced no significant change in serum creat-
nine (baseline: 1.16  0.8 mg/dl; post-procedure: 1.14 
.7 mg/dl). The median number of post-procedural creati-
ine measurements was 1 for patients with glucose 110
g/dl and 2 in all other glucose groups. The median
umber of coronary angiograms performed during AMI
ospitalization was 1, and the median number of PCI proce-
ures during hospitalization was 1 across all 5 of the glucose
roups. Overall, 43% of all patients underwent diagnostic
oronary angiography only, 50% underwent single-vessel PCI,
nd 7% underwent multivessel PCI. Median hospital length of
tay was 113 h (interquartile range: 74 to 193 h) and is
tratified by glucose level in Table 1.
Compared with patients who had lower pre-procedural
lucose, greater proportions of those with higher glucose were
emale and had prior heart failure, AMIs, and diabetes.
yperglycemic patients also had lower GFRs, had higher peak
roponin levels and lower hematocrit on admission, and were
reated more frequently with diuretics, angiotensin-converting
nzyme inhibitors or angiotensin receptor blockers, oral anti-
yperglycemic agents, and insulin. Periprocedural infusions of
odium bicarbonate, in-hospital PCI, and in-hospital CABG
ere used more frequently in patients with higher glucoseevels.
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Glucose and Contrast-Induced Acute Kidney Injury April 6, 2010:1433–40re-procedural glucose and CI-AKI. In unadjusted anal-
ses, higher pre-procedural glucose levels were strongly
ssociated with higher rates of CI-AKI (Table 2). However,
he nature of the relationship between glucose levels and
I-AKI was significantly different in patients with and
ithout known diabetes (pre-procedural glucose  diabetes
nteraction p 0.001). There was a strong association between
lucose and CI-AKI risk in patients without diabetes (CI-AKI
ates across the 5 glucose groups from lowest to highest: 8.2%,
.9%, 12.4%, 14.9%, and 24.3%; p  0.001). In contrast, no
ignificant relationship was observed between glucose levels
aseline Characteristics of AMI Patients Undergoing Coronary Angtratified by Pre-P ocedural Glucose Conce trati nTable 1 B seline Characteristics of AMI Patie ts Undergoing CStratified by Pre-Procedural Glucose Concentration
Characteristic
<110
(n  1,814)
110–<1
(n  1,8
Demographics
Age (yrs) 64 14 64 1
Female 671 (37) 588 (31)
White 1,472 (84) 1,598 (87)
Medical history
Hypertension 973 (54) 993 (53)
Diabetes 225 (12) 311 (16)
Chronic obstructive lung disease 206 (11) 176 (9)
Prior AMI 205 (11) 236 (12)
Prior heart failure 404 (22) 413 (22)
Prior stroke 50 (3) 38 (2)
Peripheral vascular disease 110 (6) 96 (5)
In-hospital medications
Aspirin 1,609 (89) 1,669 (88)
Other antiplatelet agent 1,218 (67) 1,365 (72)
Beta-blocker 1,632 (90) 1,711 (90)
ACE inhibitor or ARB 1,205 (66) 1,331 (70)
Calcium-channel blocker 411 (23) 402 (21)
Diuretic 751 (41) 799 (42)
Nitrate 1,467 (81) 1,565 (83)
Statin 1,226 (68) 1,309 (69)
Oral antihyperglycemic agent 67 (4) 86 (5)
Any insulin 271 (15) 327 (17)
Laboratory studies
Leukocyte count (1,000/l) 10 4 10 7
Hematocrit (%) 36 14 39 1
Baseline creatinine (mg/dl) 1.26 1.07 1.20 0
Estimated GFR (ml/min) 75 30 75 2
Peak troponin (ng/ml) 48 164 74 1
In-hospital management
Cardiogenic shock 24 (1) 46 (2)
Intra-aortic balloon pump 73 (4) 109 (6)
PCI
Single-vessel 822 (45) 1,030 (55)
Multivessel 117 (7) 124 (7)
CABG 277 (15) 275 (15)
Sodium bicarbonate infusion 251 (14) 271 (14)
Hospital length of stay (h), median (IQR) 117 (75–188) 104 (69–
ategorical variables are expressed as n (%) and continuous variables as mean  SD, unless oth
ACE angiotensin-converting enzyme; AMI acute myocardial infarction; ARB angiotensin re
f Diet in Renal Disease study equation); IQR  interquartile range; PCI  percutaneous coronarynd CI-AKI in patients with established diabetes (CI-AKI 2ates across the 5 glucose groups from lowest to highest:
0.9%, 16.1%, 16.3%, 14.8%, and 19.2%; p  0.24).
After adjusting for confounders (including baseline
FR), the nature of these relationships between glucose
evels and CI-AKI risk persisted (Fig. 1). In patients
ithout known diabetes, there was a gradual, incremental
ncrease in the risk for CI-AKI associated with higher
re-procedural glucose levels (odds ratios [95% confidence
ntervals] for glucose groups of 110 to 140 mg/dl, 140 to
170 mg/dl, 170 to 200 mg/dl, and 200 mg/dl: 1.31
1.00 to 1.71], 1.51 [1.11 to 2.10], 1.58 [1.03 to 2.43], and
phy (n  6,358),ary A giography (n  6,358),
ose Concentration (mg/dl)
140–<170
(n  1,086)
170–<200
(n  533)
>200
(n  1,034) p Value
66 13 66 12 65 12 0.002
411 (38) 199 (37) 442 (43) 0.001
897 (85) 458 (88) 843 (84) 0.024
598 (55) 314 (59) 533 (52) 0.047
344 (32) 278 (52) 771 (75) 0.001
108 (10) 45 (8) 102 (10) 0.187
99 (9) 42 (8) 113 (11) 0.008
306 (28) 172 (32) 410 (40) 0.001
27 (2) 19 (4) 33 (3) 0.189
58 (5) 31 (6) 39 (4) 0.115
939 (86) 459 (86) 879 (85) 0.026
766 (71) 368 (69) 697 (67) 0.008
975 (90) 470 (88) 901 (87) 0.049
786 (72) 397 (74) 763 (74) 0.001
203 (19) 119 (22) 249 (24) 0.033
494 (45) 298 (56) 614 (59) 0.001
888 (82) 453 (85) 857 (83) 0.207
755 (70) 363 (68) 714 (69) 0.777
121 (11) 107 (20) 260 (25) 0.001
283 (26) 212 (40) 620 (60) 0.001
11 4 11 6 11 4 0.001
38 11 38 10 38 12 0.001
1.22 0.81 1.35 1.02 1.38 1.09 0.001
71 28 68 29 67 31 0.001
78 126 74 133 92 240 0.001
68 (6) 37 (7) 118 (11) 0.001
98 (9) 51 (10) 141 (14) 0.001
0.001
572 (53) 262 (49) 511 (49)
83 (8) 33 (6) 73 (7)
169 (16) 103 (19) 183 (18) 0.034
173 (16) 94 (18) 243 (24) 0.001
109 (73–197) 130 (82–213) 131 (83–212) 0.001
tated.
blocker; CABG coronary artery bypass grafting; GFR glomerular filtration rate (by Modification
ntion.iograron
Gluc
40
91)
3
2
.84
7
27
181)
erwise s.14 [1.46 to 3.14], respectively, vs. glucose 110 mg/dl).
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April 6, 2010:1433–40 Glucose and Contrast-Induced Acute Kidney Injuryowever, no significant increase in glucose-associated risk
or CI-AKI was seen among patients with established
iabetes (corresponding odds ratios [95% confidence inter-
als]: 0.71 [0.44 to 1.14], 0.82 [0.52 to 1.30], 0.73 [0.45 to
.12], and 0.94 [0.63 to 1.40]; adjusted p value for glucose
diabetes interaction  0.04). In 3 sensitivity analyses—
rst excluding patients who underwent CABG within 48 h
f coronary angiography, second adjusting for the rates of
ardiogenic shock, and third using a different definition of
I-AKI—the results were similar (data not shown).
econdary analyses. Among patients without known dia-
etes, the relationship between pre-procedural glucose levels
nd the risk for CI-AKI differed according to baseline GFR
Fig. 2). There was a graded, significant relationship be-
ween higher pre-procedural glucose levels and greater risk
or CI-AKI in patients with GFR 60 ml/min (CI-AKI
ates across the 5 glucose groups from lowest to highest: 6%,
%, 9%, 10%, and 18%; p 0.001) and in those with GFRs
f 30 to 59 ml/min (11%, 16%, 19%, 18%, and 27%,
espectively; p 0.003). However, the relationship between
lucose and CI-AKI was not significant among patients
ith severely impaired renal function (GFR 30 ml/min),
s risk remained high regardless of glucose level (CI-AKI
ates across the 5 glucose groups from lowest to highest:
9%, 30%, 33%, 44%, and 44%; p  0.66).
Figure 1 Glucose and Risk of CI-AKI
Relationship between pre-procedural glucose levels and risk for contrast-induced a
angiography in acute myocardial infarction patients with and without known diabet
nadjusted Rates of CI-AKI According to Pre-Procedural Glucose LeTable 2 Unadjusted Rates of CI-AKI According to Pre-Procedura
Patient Subgroup <110 110–<140
Entire cohort 177/1,814 (9.8) 207/1,891 (11.0)
Patients without known diabetes 130/1,589 (8.2) 157/1,580 (9.9)
Patients with known diabetes 47/225 (20.9) 50/311 (16.1)
alues are expressed as n (%) of patients experiencing CI-AKI. *Interaction term for pre-procedura
CI-AKI  contrast-induced acute kidney injury.Among patients with established diabetes, there was no
ignificant association between pre-procedural glucose levels
nd CI-AKI rates in any of the GFR subgroups (data not
hown).
iscussion
n this large sample of AMI patients undergoing coronary
ngiography, we found that the nature of the relationship
etween pre-procedural glucose levels and the risk for
I-AKI was markedly different among patients with and
ithout established diabetes. Elevated glucose was common
nd associated with a steep incremental increase in the risk
or CI-AKI after coronary angiography among patients who
id not have known diabetes. In contrast, no such associa-
ion was observed among patients with established diabetes,
ho experienced high CI-AKI rates regardless of pre-
rocedural glucose levels. Importantly, glucose-associated
I-AKI risk was as high or even higher in patients without
iabetes who had significant pre-procedural hyperglycemia,
s in those with established diabetes. Moreover, the rela-
ionship between higher pre-procedural glucose and greater
I-AKI risk was particularly pronounced in those patients
ithout diabetes who did not have significantly impaired
enal function, a group that is not currently considered to be
t high risk for CI-AKI. Our findings imply that, at a
idney injury (CI-AKI) after coronary
r multivariate adjustment. CI  confidence interval.
cose Level
cose Level (mg/dl)
140–<170 170–<200 >200 p Value
148/1,086 (13.6) 79/533 (14.8) 212/1,034 (20.5) 0.001
92/742 (12.4) 38/255 (14.9) 64/263 (24.3) 0.001
56/344 (16.3) 41/278 (14.8) 148/771 (19.2) 0.24*
se and diabetes: p  0.001.cute k
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Glucose and Contrast-Induced Acute Kidney Injury April 6, 2010:1433–40inimum, hyperglycemic patients without known diabetes
hould be recognized as a high-risk group for CI-AKI and
hould be considered for prophylactic measures similar to
hose used in other high-risk patients.
rior studies of hyperglycemia. This study is the first, to
ur knowledge, to demonstrate that elevated pre-procedural
lucose levels are associated with increased risk for CI-AKI
n AMI patients without diabetes undergoing coronary
ngiography. However, the relationship between hypergly-
emia and renal injury has been previously described in
ther patient populations. Specifically, prior studies have
emonstrated a relationship between higher glucose levels
nd greater risk for acute renal failure among critically ill
atients hospitalized in intensive care units (27). Elevated
re- and perioperative glucose levels are also independently
ssociated with higher risk for post-operative renal dysfunc-
ion among patients undergoing cardiac surgery (28,29); in
act, pre-operative glucose 140 mg/dl has been incorpo-
ated into a prediction model of post-operative kidney injury
n this patient population (28). A few relatively small,
ingle-center studies also suggested that pre-diabetes may
ncrease the risk for contrast-induced nephropathy in pa-
ients with chronic kidney disease who undergo elective
oronary angiography (30) and that metabolic syndrome
ay increase the risk for acute renal failure in patients with
MIs (31). Our study adds substantially to these data by
emonstrating in a large, multicenter cohort that pre-
rocedural hyperglycemia markedly elevates the risk for
I-AKI in patients without established diabetes, even after
ccounting for baseline renal function and a multitude of
ther factors.
linical implications. Our findings have several poten-
ially important clinical implications. First, although diabe-
es is a well-known predictor of contrast nephropathy
10,12,14), elevated pre-procedural glucose levels in patients
ithout established diabetes are not currently recognized by
linicians as a risk factor for contrast-mediated renal injury.
Figure 2 Glucose and CI-AKI Rates Across GFR Subgroups
Relationship between pre-procedural glucose levels and contrast-induced acute kid
glomerular filtration rate (GFR) (calculated using the Modification of Diet in Renal Dince hyperglycemia occurs in over 40% of AMI patients, (early half of whom have no known diabetes (19,22,32),
his group of patients should at least be considered to be at
s high a risk for CI-AKI as those with established diabetes.
I-AKI prophylaxis may need to be considered in these
atients, as well as careful monitoring of post-procedural
enal function. Second, elevated pre-procedural glucose may
epresent a modifiable intervention target for CI-AKI
revention. Whether hyperglycemia is a marker of increased
omorbidity burden and disease severity or a direct mediator
f CI-AKI is unknown, but prior studies have demonstrated
ncreased oxidative stress, blunting of free radical scaven-
ers, decreased levels of nitric oxide, and endothelial dys-
unction in the setting of elevated glucose (33–42). Other
nvestigators have shown enhanced susceptibility to isch-
mic and reperfusion injury in animal models of experimen-
ally induced hyperglycemia (43). Since numerous studies
ave shown that similar pathophysiologic mechanisms are
lso involved in contrast nephropathy (3,14,15), the effects
f hyperglycemia in our analysis may reflect a “double insult”
o renal function that previously has not been described in
atients without established diabetes. Although no conclu-
ions regarding a possible cause-and-effect relationship be-
ween hyperglycemia and CI-AKI can be drawn from our
tudy, several randomized trials in critically ill patients have
emonstrated that glycemic control with insulin may reduce
he rates of acute renal failure (44–46). Because the findings
f these clinical trials cannot be automatically extrapolated
o AMI patients undergoing coronary angiography, pro-
pective randomized studies are needed to determine
hether glucose control can reduce the rates of CI-AKI in
he setting of AMI.
The reasons behind the different relationships between
lucose levels and CI-AKI risk among patients with and
ithout known diabetes are unclear but have been previ-
usly described with other outcomes, such as mortality
19–22). Several possible explanations exist for this phe-
omenon. First, as previously demonstrated in other studies
jury (CI-AKI) across subgroups of
e study equation) in patients without known diabetes.ney in
iseas19,32), hyperglycemic AMI patients without known dia-
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April 6, 2010:1433–40 Glucose and Contrast-Induced Acute Kidney Injuryetes typically receive much less aggressive therapy for
lucose control compared with those who have known
iabetes. Since intensive glucose control with insulin has
een previously shown to reduce the rates of renal injury in
ritically ill patients (44,46,47), this significant discrepancy
n treatment rates may have an effect on glucose-associated
I-AKI rates. Second, since diabetes is a well-recognized
isk factor for CI-AKI, patients with diabetes may receive
ore aggressive pre-procedural CI-AKI prophylaxis, atten-
ating the potential effect of hyperglycemia on renal injury.
hird, some hyperglycemic AMI patients without known
iabetes (particularly those with glucose 200 mg/dl) may
ctually have diabetes that has been neither recognized nor
dequately managed and thus may represent a higher-risk
ohort for the development of CI-AKI. Even if not definitively
iagnosed with diabetes by hospital discharge, hyperglycemia
n AMI patients likely represents glucose dysmetabolism, and
he simple act of evaluating pre-catheterization glucose should
lert clinicians to the elevated risk for renal injury. Finally, it
s also possible that a greater degree of stress (illness
everity) is needed for patients without established diabetes
o achieve the same degree of hyperglycemia as their
ounterparts with diabetes. However, the difference in the
ssociation between hyperglycemia and CI-AKI among
atients with and without known diabetes persisted even
fter accounting for disease severity indicators, including
nfarct size.
tudy limitations. The results of our study should be
nterpreted in the context of several potential limitations.
irst, the volume of contrast administered in each procedure
as not available; however, we believe that by using the
erformance of PCI (including the differentiation between
ingle-vessel and multivessel PCI) in the multivariable
odels, we introduced a surrogate for presumed higher
ontrast volume (compared with diagnostic angiography
lone). Moreover, there is no a priori reason to expect that
yperglycemic patients would be more likely to receive
arger or smaller doses of contrast material than normogly-
emic patients. Second, although we rigorously attempted
o account for baseline differences between patients in
ifferent pre-procedural glucose groups, residual confound-
ng cannot be excluded. Specifically, we were unable to
ontrol for certain clinical variables, such as the presence of
T-segment elevation and left ventricular ejection fraction.
owever, adjustment for ST-segment elevation and ejec-
ion fraction did not affect the nature of glucose-associated
isk for mortality in our prior studies (19), and we were able
o control for other variables, such as infarct size (using peak
roponin levels) and numerous other patient factors. Third,
ur data are limited to AMI patients undergoing angiogra-
hy, and the relationship between hyperglycemia and CI-
KI in other patient populations or with other diagnostic
odalities requiring intravenous contrast (e.g., computed
omography scans, other angiograms) remains unclear.
ourth, we do not know how many of those patients
ithout known diabetes were subsequently diagnosed withiabetes after discharge; however, our specific focus was to
valuate the CI-AKI risk associated with pre-procedural
lucose values in patients who were not recognized as
aving diabetes at the time of AMI hospitalization. Finally,
lthough we adjusted for sodium bicarbonate administration
n our analyses, we were unable to determine whether
lucose lowering with insulin or the use of other prophy-
actic CI-AKI therapies (e.g., intravenous hydration or
-acetylcysteine) could reduce the risk for CI-AKI in
yperglycemic AMI patients without established diabetes.
his will need to be determined in future prospective
nvestigations.
onclusions
n summary, elevated pre-procedural glucose levels are
ssociated with greater risk for CI-AKI in AMI patients
ithout established diabetes who undergo coronary angiog-
aphy. Close monitoring of post-procedural renal function
nd prophylactic therapies used to prevent CI-AKI should
e considered in this patient group.
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